Barclays PLC Cabaletta Bio, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 61,130 shares of CABA stock, worth $139,987. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,130

Previous 61,130 -0.0%

Holding current value

$139,987

Previous $288,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.94 - $8.24 $78,370 - $163,901	19,891 Added 48.23%	61,130 $288,000
Q2 2024 Aug 14, 2024	SELL	$7.22 - $18.82 $55,803 - $145,459	-7,729 Reduced 15.78%	41,239 $308,000
Q1 2024 May 15, 2024	SELL	$16.79 - $25.38 $1.34 Million - $2.03 Million	-80,104 Reduced 62.06%	48,968 $834,000
Q4 2023 Feb 15, 2024	BUY	$12.21 - $23.36 $787,374 - $1.51 Million	64,486 Added 99.85%	129,072 $2.93 Million
Q3 2023 Nov 07, 2023	BUY	$11.84 - $18.65 $704,361 - $1.11 Million	59,490 Added 1167.39%	64,586 $984,000
Q2 2023 Aug 03, 2023	SELL	$7.65 - $13.95 $475,080 - $866,322	-62,102 Reduced 92.42%	5,096 $65,000
Q1 2023 May 04, 2023	BUY	$7.08 - $12.62 $446,408 - $795,716	63,052 Added 1520.79%	67,198 $555,000
Q4 2022 Feb 13, 2023	BUY	$0.64 - $9.3 $1,872 - $27,202	2,925 Added 239.56%	4,146 $38,000
Q3 2022 Nov 03, 2022	SELL	$0.63 - $2.05 $8,783 - $28,581	-13,942 Reduced 91.95%	1,221 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.99 - $2.11 $550 - $1,173	-556 Reduced 3.54%	15,163 $16,000
Q1 2022 May 16, 2022	BUY	$1.68 - $3.92 $26,407 - $61,618	15,719 New	15,719 $32,000

Others Institutions Holding CABA

# of Institutions

126

Shares Held

47.9M

Call Options Held

202K

Put Options Held

110K

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account